Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Adenomatous Polyposis Coli × 90 days × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 107 Breast Neoplasms 106 Prostatic Neoplasms 55 Neoplasms 49 Multiple Myeloma 45 Lung Neoplasms 34 Parkinson Disease 4, Autosomal Dominant Lewy Body 32 Colorectal Neoplasms 32 Neoplasm Metastasis 30 Ovarian Neoplasms 27 Stomach Neoplasms 24 Myasthenia Gravis 23 Leukemia, Lymphocytic, Chronic, B-Cell 23 Urinary Bladder Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 22 Leukemia, Myeloid, Acute 22 Lymphoma, Follicular 21 Carcinoma, Hepatocellular 21 Recurrence 19 Melanoma 19 Lymphoma, Large B-Cell, Diffuse 18 Carcinoma, Renal Cell 18 Small Cell Lung Carcinoma 17 Brain Neoplasms 17 Endometrial Neoplasms 16 Colonic Neoplasms 16 Lymphoma 14 Carcinoma 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06950385 2026-03-17

SERENTA

Rapamycin Holdings Inc.

Phase 3 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Polyps

Data powered by HemOnc (CC BY 4.0) Colophon ⚡